media – Pharma & Medical Industry Insights Hub | Drugdu Insights & Updates

【EXPERT Q&A】What is the effect of rukang saltuzumab on EGFR-mutated lung cancer?

Drugdu.com expert’s response: I. Clinical Research Data KL264-01 Study: In the subgroup analysis targeting EGFR-mutated non-small cell lung cancer (NSCLC) patients, the objective response rate (ORR) of sacituzumab tirumotecan as a monotherapy reached as high as 55%, with a median progression-free survival (PFS) of 11.1 months. These results were significantly superior to those in EGFR wild-type patients, who had an ORR of 24% and a median PFS of 5.3 months. SKB264-II-08 Study: Among 64 previously treated EGFR-mutated NSCLC patients, sacituzumab tirumotecan achieved an ORR of 34%, a disease control rate (DCR) of 84%, a median duration of response (DOR) of 9.6 months, a median PFS of 9.3 months, and a 1-year overall survival (OS) rate of 79%. OptiTROP-Lung03 Study: The sacituzumab tirumotecan group demonstrated a confirmed ORR of 45.1%, significantly higher than the 15.6% in the docetaxel group. The median PFS was 6.9 months, significantly longer than the 2.8 months ...
- Source: drugdu
- 36
- June 13, 2025
The first precision treatment drug for ALS has been launched; Chen Shoujun, a core technical personnel of Huiyu Pharmaceutical, has resigned from the company. Health News Daily

Policy Tendence National Health Commission: Promote the construction of compact urban medical groups in 81 pilot cities across the country On June 10th, the relevant person in charge of the National Health Commission stated that in accordance with the overall requirement of “major illnesses should not leave the province, general illnesses should be solved in cities and counties, and daily illnesses should be solved at the grassroots level”, firstly, the construction of national medical centers and national regional medical centers should be promoted, which is commonly referred to as the “dual center” construction. Secondly, we should focus on the construction of urban medical groups. Promote the construction of compact urban medical groups in 81 pilot cities across the country, and promote the sharing of medical resources. In addition, by the end of 2024, 2188 counties (cities, districts) across the country have promoted the construction of close county-level medical communities, ...
- Source: drugdu
- 46
- June 12, 2025
Sinopharm plans to transfer 100% equity of Tong’an Pharmaceutical; Lianhuan Pharmaceutical was fined over 61 million yuan due to a monopoly agreement | Medical Early Ginseng

No.1 Kexing Pharmaceutical plans to transfer 100% equity of Tong’an Pharmaceutical for 15 million yuan On June 10th, Sinopharm announced that it plans to transfer 100% equity of its wholly-owned subsidiary Shenzhen Tong’an Pharmaceutical Co., Ltd. to Guangxi Zhuang Autonomous Region Institute of Materia Medica Co., Ltd. for a transfer price of 15 million yuan. According to the announcement, Tong’an Pharmaceutical has not actually conducted business in recent years. Currently, it mainly holds approval numbers for 20 drugs, including 19 traditional Chinese medicine varieties such as Vitamin C Yinqiao tablets. After the transaction is completed, Sinopharm will no longer hold equity in Tong’an Pharmaceutical, and Tong’an Pharmaceutical will no longer be included in the company’s consolidated financial statements. Comment: The sale of equity in Tong’an Pharmaceutical by Kexing Pharmaceutical is beneficial for the company to continue focusing on the biopharmaceutical field, improve core competitiveness, reduce operational risks, and is ...
- Source: drugdu
- 44
- June 12, 2025
Blood Tests Can Detect Cancer Years Earlier

By Dennis Thompson HealthDay ReporterTUESDAY, June 10, 2025 (HealthDay News) — Blood tests can detect evidence of cancer three years earlier than the disease would otherwise be diagnosed, a new small-scale pilot study says. The test — called a multicancer early detection (MCED) test — looks for genetic material that’s shed by tumors into the bloodstream. The test revealed cancer DNA that was circulating in some patients’ blood up to three-and-a-half years prior to their diagnosis with cancer, according to results recently published in the journal Cancer Discovery. “Detecting cancers years before their clinical diagnosis could help provide management with a more favorable outcome,” said senior researcher Nickolas Papadopoulos, a professor of oncology at the Ludwig Center at Johns Hopkins in Baltimore. “Of course, we need to determine the appropriate clinical follow-up after a positive test for such cancers,” he added in a news release. For the study, researchers assessed ...
- Source: drugdu
- 36
- June 12, 2025
Statins Appear Effective In Treating Sepsis

By Dennis Thompson HealthDay ReporterTUESDAY, June 10, 2025 (HealthDay News) — Statins are a gold-standard treatment for lowering cholesterol, but a new study shows the inexpensive drugs could provide another life-saving service. Patients with sepsis appear to have a lower risk of dying if they’re treated with statins along with the usual cocktail of antibiotics, intravenous fluids and drugs to increase blood pressure, researchers reported June 5 in the journal Frontiers in Immunology. “Treatment with statins was associated with a 39% lower death rate for critically ill patients with sepsis, when measured over 28 days after hospital admission,” lead researcher Dr. Caifeng Li, an associate professor at Tianjin Medical University General Hospital in China, said in a news release. Sepsis is a medical emergency in which the immune system has an overwhelming inflammatory response to an infection. The response is so powerful that the vital organs begin to shut down. ...
- Source: drugdu
- 38
- June 12, 2025
The National Medical Products Administration conducts management review of the quality management system for vaccine supervision and drug production inspection

On the 9th, the National Medical Products Administration conducted a management review of the 2024 vaccine supervision and drug production inspection quality management system (vaccine QMS and drug production inspection QMS). Li Li, Secretary of the Party Leadership Group and Director of the State Drug Administration, pointed out that the State Drug Administration has continued to deepen the effective operation of the vaccine QMS, coordinated and promoted the smooth start of the drug production inspection QMS, fully utilized the role of the quality management system in monitoring and reviewing the entire process, and continuously improved the work related to drug supervision. The vaccine QMS and drug production inspection QMS of the State Drug Administration are appropriate, sufficient and effective, and the work has achieved remarkable results. Through the hierarchical and classified management of drug inspectors, high-level training of drug inspectors, and the training of a group of backbone inspectors with ...
- Source: drugdu
- 35
- June 12, 2025
Keqian Bio intends to sign a joint vaccine research and development agreement with Huazhong Agricultural University

June 10, Keqian Biology(688526) announced that it plans to sign a “Swine Mycoplasma Pneumonia, Swine Flu” contract with Huazhong Agricultural UniversityA joint research and development agreement on a two-inactivated vaccine (XJ03 strain + HN strain + SD strain) for H1N1 and H3N2. This transaction constitutes a related-party transaction, as a wholly-owned subsidiary of Huazhong Agricultural University holds 16.73% of the company’s shares, and many directors have direct ties with the university. Both parties will jointly bear the various experimental expenses, technical achievements and intellectual property rights　　required during the research and development process.Belong to both parties jointly. In the first quarter of 2025, Keqian Bio achieved revenue of 245 million yuan and net profit attributable to shareholders of the parent company of 108 million yuan. https://finance.eastmoney.com/a/202506103426820044.html
- Source: drugdu
- 34
- June 12, 2025
Plans to transfer 100% equity of Tongan Pharmaceutical to continue focusing on the biopharmaceutical track

Kexing Pharmaceuticals(688136) announced on June 11, the company plans to transfer 100% equity of its wholly-owned subsidiary Shenzhen Tongan Pharmaceutical Co., Ltd. for RMB 15 million.To Guangxi Zhuang Autonomous Region Drug Research Institute Co., Ltd. The company’s stock closed at 56.39 yuan per share on June 10, up 6.40%. Guangxi Pharmaceutical Research Institute is a high-tech enterprise dedicated to pharmaceutical research and development and innovation .Enterprise, Guangxi Specialized, Refined, Special and New Enterprise. It has 5 national exclusive varieties and nearly 40 product approvals. Its credit status is good, it has not been listed as a dishonest debtor, and it has the ability to perform its contracts. Tongan Pharmaceutical’s original main business was to produce Kehuang Capsules on behalf of the company. Now the drug has been transferred to the company’s own production. In recent years, Tongan Pharmaceutical has not actually carried out business. At present, it mainly holds 19 ...
- Source: drugdu
- 35
- June 12, 2025
LifeSense’s subsidiary’s application for renewal of Holter system registration certificate accepted

June 10, LifeSense issued an announcement that its holding subsidiary Ruikang Hongye recently received a medical deviceThe “Acceptance Certificate” for the renewal of the registration certificate has the acceptance number 0010600220250626. The product involved in this renewal application is a dynamic electrocardiogram system, which is a Class II medical device . Its registration certificate will expire on December 14, 2025, and the application renewal period is five years. In the first quarter of 2025, Lepu Medical achieved revenue of 273 million yuan and net profit attributable to shareholders of the parent company of 22.94 million yuan. https://finance.eastmoney.com/a/202506103426761085.html
- Source: drugdu
- 34
- June 12, 2025
MEDIX Japan

Organiser: Reed Exhibitions Time： October 1st – October 3rd, 2025 address：1-5-102 Minatonomori-kita, Suminoe-ku, Osaka-shi, Osaka Prefecture, Japan Exhibition hall： Intex Osaka Product range: Medical components and parts Various medical motors, electric machines, and functional components Medical pumps and valves Medical electronic components, modules, and accessories Surface treatments and coatings Tubing and extrusion processing Medical device contract manufacturing services Medical needles/tubing Various medical materials, including titanium alloys, PVC materials, etc. About MEDIX Japan： The MEDIX Japan Osaka Medical Device Exhibition is the largest-scale and highest-level exhibition for medical device components and materials in Western Japan. It brings together a comprehensive range of offerings in medical device design and development, raw materials, components, manufacturing equipment, contract customization, testing, and certification. It serves as the optimal platform for component enterprises to promote their products to medical device manufacturers.
- Source: drugdu
- 35
- June 12, 2025

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.